These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 27009092)

  • 1. Health-related quality of life of postmenopausal Chinese women with hormone receptor-positive early breast cancer during treatment with adjuvant aromatase inhibitors: a prospective, multicenter, non-interventional study.
    Cao A; Zhang J; Liu X; Wu W; Liu Y; Fan Z; Zhang A; Zhou T; Fu P; Wang S; Ouyang Q; Tang J; Jiang H; Zhang X; Pang D; He J; Shi L; Wang X; Sheng Y; Mao D; Shao Z
    Health Qual Life Outcomes; 2016 Mar; 14():51. PubMed ID: 27009092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aromatase Inhibitors in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer: Profiles of Psychological Symptoms and Quality of Life in Different Patient Clusters.
    Borreani C; Alfieri S; Infante G; Miceli R; Mariani P; Bosisio M; Vernieri C; Bianchi GV; Capri G
    Oncology; 2021; 99(2):84-95. PubMed ID: 32992318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone metabolism and quality-of-life of postmenopausal women with invasive breast cancer receiving neoadjuvant hormonal therapy: sub-analyses from celecoxib anti-aromatase neoadjuvant (CAAN) trial.
    Chow LW; Yip AY; Chu WP; Loo WT; Toi M
    J Steroid Biochem Mol Biol; 2011 May; 125(1-2):112-9. PubMed ID: 21236344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-reported oral health and quality of life of postmenopausal breast cancer survivors on aromatase inhibitors and women without cancer diagnoses: a longitudinal analysis.
    Taichman LS; Van Poznak CH; Inglehart MR
    Support Care Cancer; 2016 Nov; 24(11):4815-24. PubMed ID: 27455851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy.
    Sheng JY; Blackford AL; Bardia A; Venkat R; Rosson G; Giles J; Hayes DF; Jeter SC; Zhang Z; Hayden J; Nguyen A; Storniolo AM; Tarpinian K; Henry NL; Stearns V
    Breast Cancer Res Treat; 2019 Aug; 176(3):617-624. PubMed ID: 31079282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation.
    Fallowfield LJ; Kilburn LS; Langridge C; Snowdon CF; Bliss JM; Coombes RC;
    Br J Cancer; 2012 Mar; 106(6):1062-7. PubMed ID: 22353807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aromatase inhibitors in postmenopausal breast cancer patients.
    Rieber AG; Theriault RL
    J Natl Compr Canc Netw; 2005 May; 3(3):309-14. PubMed ID: 16002003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial.
    Fallowfield L; Cella D; Cuzick J; Francis S; Locker G; Howell A
    J Clin Oncol; 2004 Nov; 22(21):4261-71. PubMed ID: 15514369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer.
    Yu KD; Zhou Y; Liu GY; Li B; He PQ; Zhang HW; Lou LH; Wang XJ; Wang S; Tang JH; Liu YH; Wang X; Jiang ZF; Ma LW; Gu L; Cao MZ; Zhang QY; Wang SM; Su FX; Zheng H; Li HY; Tang LL; Sun SR; Liu JP; Shao ZM; Shen ZZ
    Breast Cancer Res Treat; 2012 Jul; 134(1):307-13. PubMed ID: 22527106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials.
    Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
    J Bone Miner Metab; 2019 Sep; 37(5):864-870. PubMed ID: 30868270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials.
    Qian X; Li Z; Ruan G; Tu C; Ding W
    Breast Cancer Res Treat; 2020 Jan; 179(2):275-285. PubMed ID: 31606823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physical activity and health-related quality of life among postmenopausal women with breast cancer treated with aromatase inhibitors.
    Dibble KE; Bellizzi KM; Taxel P; Pescatello LS; Siembida EJ; Schifano ED; Guarneri S; Tannenbaum S
    Support Care Cancer; 2021 May; 29(5):2385-2394. PubMed ID: 32918610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world assessment of quality-of-life in patients with breast cancer treated with adjuvant endocrine therapy.
    Akin Telli T; Ozturk MA; Alan O; Hasanov R; Kostek O; Arikan R; Basoglu T; Kaya S; Ercelep O; Akgul Babacan N; Dane F; Yumuk PF
    Future Oncol; 2022 Jul; 18(22):2425-2439. PubMed ID: 35695547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Menopausal symptoms in relationship to breast cancer-specific quality of life after adjuvant cytotoxic treatment in young breast cancer survivors.
    Yeo W; Pang E; Liem GS; Suen JJS; Ng RYW; Yip CCH; Li L; Yip CHW; Mo FKF
    Health Qual Life Outcomes; 2020 Feb; 18(1):24. PubMed ID: 32041627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients.
    Crew KD; Capodice JL; Greenlee H; Apollo A; Jacobson JS; Raptis G; Blozie K; Sierra A; Hershman DL
    J Cancer Surviv; 2007 Dec; 1(4):283-91. PubMed ID: 18648963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acupoint Thread Embedding Combined With Wenshen Bugu Decoction for the Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptom Among Postmenopausal Breast Cancer Patients: Study Protocol of a Randomized Controlled Trial.
    Zou X; Chen ZY; Yang YH; Qiao Y; He SJ; Li Q; Chen WL; Zhang XY; Li SY; Sha SY; Hu MH; Zhang XY; Yang MJ; Wang RP; Wu HG; Shi Y; Xue XH; Ji YJ
    Integr Cancer Ther; 2023; 22():15347354231188679. PubMed ID: 37565358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of using adjuvant aromatase inhibitors on cognitive functions in postmenopausal women with hormone receptor-positive breast cancer.
    Ilhan RG; Ilhan Y; Goksu SS; Tatli AM; Coskun HS
    J Cancer Res Ther; 2023 Apr; 19(Supplement):S0. PubMed ID: 37147957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.
    Kahan Z; Gil-Gil M; Ruiz-Borrego M; Carrasco E; Ciruelos E; Muñoz M; Bermejo B; Margeli M; Antón A; Casas M; Csöszi T; Murillo L; Morales S; Calvo L; Lang I; Alba E; de la Haba-Rodriguez J; Ramos M; López IÁ; Gal-Yam E; Garcia-Palomo A; Alvarez E; González-Santiago S; Rodríguez CA; Servitja S; Corsaro M; Rodrigálvarez G; Zielinski C; Martín M
    Eur J Cancer; 2021 Oct; 156():70-82. PubMed ID: 34425406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.